Maa: Kanada
Kieli: englanti
Lähde: Health Canada
TIMOLOL (TIMOLOL MALEATE)
SANDOZ CANADA INCORPORATED
S01ED01
TIMOLOL
0.25%
SOLUTION
TIMOLOL (TIMOLOL MALEATE) 0.25%
OPHTHALMIC
5ML/10ML
Prescription
BETA-ADRENERGIC AGENTS
Active ingredient group (AIG) number: 0131275001; AHFS:
APPROVED
1999-10-07
_ _ _ _ _Sandoz Timolol _ _Page 1 of 25_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr SANDOZ TIMOLOL Timolol Maleate Ophthalmic Solution Solution, 0.25%, 0.5% w/v timolol (as timolol maleate), ophthalmic USP Antiglaucoma Preparations and Miotics Sandoz Canada Inc. 110 rue de Lauzon, Boucherville, QC, J4B 1E6 Date of Initial Authorization: AUG 22, 2005 Date of Revision: MAR 07, 2024 Submission Control Number: 283616 _ _ _ _ _ _ _Sandoz timolol _ _Page 2 of 25_ RECENT MAJOR LABEL CHANGES 6 Dosage Forms, Strengths, Composition and Packaging 03/2024 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES .......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION .................................................................... 4 1 INDICATIONS ............................................................................................................. 4 1.1 Pediatrics ...................................................................................................................... 4 1.2 Geriatrics ...................................................................................................................... 4 2 CONTRAINDICATIONS ................................................................................................ 4 4 DOSAGE AND ADMINISTRATION ................................................................................ 4 4.1 Dosing Considerations ................................................................................................. 4 4.2 Recommended Dose and Dosage Adjustment ............................................................ 5 4.4 Administration ............................................................................................................. 5 4.5 Missed Dose Lue koko asiakirja